Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). by Niven, Robert M et al.
Impact of omalizumab on treatment of
severe allergic asthma in UK clinical
practice: a UK multicentre observational
study (the APEX II study)
Robert M Niven,1 Dinesh Saralaya,2 Rekha Chaudhuri,3 Matthew Masoli,4
Ian Clifton,5 Adel H Mansur,6 Victoria Hacking,7 Susan McLain-Smith,8
Andrew Menzies-Gow9
To cite: Niven RM,
Saralaya D, Chaudhuri R,
et al. Impact of omalizumab
on treatment of severe
allergic asthma in UK clinical
practice: a UK multicentre
observational study (the
APEX II study). BMJ Open
2016;6:e011857.
doi:10.1136/bmjopen-2016-
011857
▸ Prepublication history and
additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/bmjopen-2016-
011857).
Received 22 March 2016
Revised 13 June 2016
Accepted 13 July 2016
For numbered affiliations see
end of article.
Correspondence to
Dr Robert M Niven;
Robert.Niven@UHSM.NHS.UK
ABSTRACT
Objective: To describe the impact of omalizumab on
asthma management in patients treated as part of
normal clinical practice in the UK National Health
Service (NHS).
Design: A non-interventional, mixed methodology
study, combining retrospective and prospective data
collection for 12 months pre-omalizumab and post-
omalizumab initiation, respectively.
Setting: Data were collected in 22 UK NHS centres,
including specialist centres and district general
hospitals in the UK.
Participants: 258 adult patients (aged ≥16 years;
65% women) with severe persistent allergic asthma
treated with omalizumab were recruited, of whom 218
(84.5%) completed the study.
Primary and secondary outcome measures: The
primary outcome measure was change in mean daily
dose of oral corticosteroids (OCS) between the 12-
month pre-omalizumab and post-omalizumab initiation
periods. A priori secondary outcome measures
included response to treatment, changes in OCS
dosing, asthma exacerbations, lung function,
employment/education, patient-reported outcomes and
hospital resource utilisation.
Results: The response rate to omalizumab at 16 weeks
was 82.4%. Comparing pre-omalizumab and post-
omalizumab periods, the mean (95% CIs) daily dose of
OCS decreased by 1.61 (−2.41 to −0.80) mg/patient/
day (p<0.001) and hospital exacerbations decreased by
0.97 (−1.19 to −0.75) exacerbations/patient (p<0.001).
Compared with baseline, lung function, assessed by
percentage of forced expiratory volume in 1 s, improved
by 4.5 (2.7 to 6.3)% at 16 weeks (p<0.001; maintained
at 12 months) and patient quality of life (Asthma Quality
of Life Questionnaire) improved by 1.38 (1.18 to 1.58)
points at 16 weeks (p<0.001, maintained at 12 months).
21/162 patients with complete employment data gained
employment and 6 patients lost employment in the
12-month post-omalizumab period. The mean number
of A&E visits, inpatient hospitalisations, outpatient
visits (excluding for omalizumab) and number of bed
days/patient decreased significantly (p<0.001) in the
12-month post-omalizumab period.
Conclusions: These data support the beneficial effects
of omalizumab on asthma-related outcomes, quality of
life and resource utilisation in unselected patients treated
in ‘real-world’ clinical practice.
Strengths and limitations of this study
▪ Data for Asthma Patient Experience with Xolair
(APEX) II were collected in a non-interventional
clinical setting, and therefore, the results reflect
the outcomes of treatment delivered according to
normal UK clinical practice, using National
Institute for Health and Care Excellence guid-
ance, but in otherwise unselected patients.
▪ The study was limited by the necessity to collect
pre-omalizumab data retrospectively, which
affected the quality and availability of data, and is
reflected in the volume of missing data for some
of the variables, leading to differences in the
number of patients for each analysis; in particu-
lar, details of OCS prescriptions provided in
primary care were limited in the pre-omalizumab
period, which may have led to underestimation
of the number of patients classified as ‘on con-
tinuous corticosteroids (CCS)’ and calculation of
the mean daily dose in the pre-omalizumab
period.
▪ The prospective data collection in the post-
omalizumab period allowed for more complete
data collection related to OCS use and
asthma-related outcomes than in the pre-
omalizumab period; in particular, details of
primary care OCS prescriptions were limited in
the pre-omalizumab period; the mixed study
design leads to a potential underestimation of
the beneficial effects of omalizumab.
▪ Data related to days off sick from work/education
were subject to recall bias in pre-omalizumab
and post-omalizumab periods; however, the data
are included due to its novelty and potential
importance to the overall societal benefit of opti-
mally treating severe asthma.
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INTRODUCTION
Asthma is a common chronic inﬂammatory disease of the
airways, with an estimated lifetime prevalence of one in
nine people in England.1 Asthma is difﬁcult to control in
many patients, with a recent European study reporting
that 76% of patients are poorly controlled, though causes
of poor control are multifactorial.2 IgE plays a central
role in mediating inﬂammatory reactions associated with
allergic asthma via interactions with high-afﬁnity recep-
tors on mast cells and basophils.3 Asthma exacerbations
are common and associated with signiﬁcant morbidity
and mortality,4 and increased serum IgE levels to
common inhaled allergens is a risk factor for asthma
exacerbations.5 6 Severe asthma is reported as occurring
in 5–10% of patients and frequently requires long-term
treatment with oral corticosteroids (OCS) or frequent
short burst use of high-dose OCS to try and improve
asthma control and prevent exacerbations, although
some patients remain poorly controlled despite this treat-
ment.7 8 OCS usage for asthma management is associated
with adverse effects, including obesity, mood distur-
bances, development of osteoporosis, fractures, glau-
coma, cataracts, endocrine and metabolic disorders,
muscle weakness and cardiovascular disorders.8–12
Therapeutic options that improve asthma control, reduce
asthma exacerbations and reduce reliance on OCS use in
patients with severe asthma are required to improve
disease-related and current therapy-related morbidity.
Omalizumab (Xolair) is a recombinant humanised
monoclonal antibody that binds to IgE and is indicated
as add-on therapy to improve asthma control in patients
with severe persistent allergic asthma.13 Omalizumab
decreases expression of high-afﬁnity IgE receptors on
inﬂammatory cells and airway accumulation of eosino-
phils.6 14 Omalizumab has been demonstrated in clinical
trials and observational studies (including a retrospective
study of patients treated with omalizumab in the UK; the
Asthma Patient Experience with Xolair (APEX) I study)
to signiﬁcantly decrease OCS use, asthma exacerbations,
Accident and Emergency (A&E) visits, hospitalisations
and bed days, and to improve asthma symptoms, lung
function and patients’ quality of life (QoL).14–16 Patients
with severe allergic asthma are at increased risk for
exacerbations requiring hospitalisation, which adversely
affects their QoL, employment, hospital resource utilisa-
tion and may result in death.16–18 There are limited
prospective data available describing the impact of oma-
lizumab on the management of patients with severe
asthma when used in a real-world clinical setting.
The aim of the APEX II study was to describe the
impact of omalizumab on asthma management in adult
patients (aged 16 years and over) being treated with
omalizumab as part of normal clinical practice within
the UK National Health Service (NHS). This was carried
out using a prospective methodology for collection of
data from the point of decision to prescribe omalizu-
mab, to address, as far as possible, the limitations of the
previous retrospective study.16
METHODS
Study design and setting
APEX II involved collecting data on patients from UK
NHS secondary care centres using omalizumab as part
of normal clinical practice, including specialist centres
and district general hospitals, from across the UK. The
study employed a mixed methodology to obtain retro-
spective data on the 12-month period prior to omalizu-
mab initiation (the pre-omalizumab period) and
prospective data at omalizumab initiation (baseline) and
during the 12-month period following omalizumab initi-
ation (the post-omalizumab period; evaluated at
16 weeks, 8 months and 12 months following omalizu-
mab initiation). Data were collected between 20 January
2012 and 1 February 2015.
Patients
All eligible adult patients (aged 16 years or over) with
severe persistent allergic (IgE-mediated) asthma for
whom omalizumab was prescribed for the ﬁrst time as
part of normal clinical practice were invited to take part
in the study by a member of the clinical team. Patients
with insufﬁcient baseline data and those who had under-
gone bronchial thermoplasty or were participating in
any interventional trial of asthma treatment were
excluded from the study. Patients gave written informed
consent according to a protocol approved by the UK
National Research Ethics Service (REC reference
number 11/LO/2025). Local hospital management
approval was obtained in each participating centre.
Data collection
Retrospective data for the 12-month pre-omalizumab
period for each patient were collected from paper-based
and electronic medical records. Where data were incom-
plete in study site medical records, additional data relat-
ing to the 12-month pre-omalizumab period were
requested from the primary/secondary care records
held by general practitioners and referring hospitals.
Prospective data were recorded by members of the clin-
ical team (usually a Clinical Nurse Specialist) during
routine clinical consultations with patients at omalizu-
mab initiation and in the post-omalizumab period
(16 weeks (±2 weeks), 8 months (±1 month) and
12 months (±1 month)). All data were collected in
anonymised-coded form on standard data collection
forms designed for the study. All staff participating in
data collection were trained in the study documentation
requirements and were required to maintain patient
conﬁdentiality and to report any adverse events to the
study sponsor in accordance with the Medicines and
Healthcare Products Regulatory Agency requirements.
Outcome measures
The primary outcome measure was the change in mean
daily dose of OCS prescribed per patient between the
12-month pre-omalizumab and post-omalizumab initi-
ation periods. Secondary outcome measures included
2 Niven RM, et al. BMJ Open 2016;6:e011857. doi:10.1136/bmjopen-2016-011857
Open Access
patient demographic and clinical characteristics;
response to treatment; proportion of patients stopping
and/or reducing OCS by ≥20% in the post-omalizumab
period; changes between the 12-month pre-omalizumab
and post-omalizumab initiation periods in the number
of asthma exacerbations (exacerbations were deﬁned as
‘hospital exacerbations’ when patients attended A&E or
were admitted and deﬁned as ‘dose exacerbations’ when
OCS dose increased by ≥10 mg at any point for at least
3 days), NHS secondary care resource utilisation,
number of working/education days lost and number of
patients employed/unemployed; changes between post-
omalizumab visits and omalizumab initiation visit in
weight, lung function (forced expiratory volume in 1 s
(FEV1(L)) and expressed as a percentage of predicted
(FEV1%)) and patient-reported outcomes (PRO; using
validated PRO measures: Asthma Control Test (ACT),
Asthma Quality of Life Questionnaire (AQLQ) and the
EuroQol ﬁve-dimensions (EQ-5D) health questionnaire).
Statistical analyses
The retrospective APEX I study16 demonstrated a reduc-
tion in mean total quantity of OCS prescribed in the
12-month period post-omalizumab initiation of 1.87 g
(SD of paired differences=2.7 g). A sample size of 250
patients was, therefore, considered to be sufﬁcient to
reliably describe a similar reduction at p=0.01.
APEX II was a non-interventional study and all ana-
lyses were conducted using the available data based on
the intention to treat (ITT). No imputation of missing
data was undertaken and the number available for each
analysis is stated where data were missing. Patient demo-
graphic and clinical characteristics were summarised for
all patients using descriptive statistics (contingency
tables for qualitative variables) and mean (SD) or
median (range) for quantitative variables. Primary and
secondary outcome measures were compared using the
Student’s t-test (comparing 12-month pre-omalizumab
and post-omalizumab initiation periods for OCS use,
asthma exacerbations, employment and resource utili-
sation (except for the number of intensive care unit
(ICU) admissions which was compared using the
McNemar test) and comparing post-omalizumab visits
(16 weeks, 8 months and 12 months) with omalizumab
initiation visit (baseline) for lung function, PROs and
weight), and reported as the mean difference with 95%
CIs and p values.
Subgroup analyses were conducted on data from the
subgroup of patients on continuous OCS for at least
6 months prior to initiation of omalizumab (baseline
continuous corticosteroid (CCS) subgroup) and separ-
ately in the subgroup classiﬁed as responders to omalizu-
mab at the 16-week assessment visit. As this was a
real-world non-interventional study, the subgroup of
responders comprised all patients who were classiﬁed by
the treating physician as responders at the 16-week
assessment according to usual clinical practice at each
centre. Participating centres were expected to be
following guidelines (based on National Institute for
Health and Care Excellence (NICE) or Scottish
Medicines Consortium (SMC) criteria); however, all
patients for whom funding was obtained from local com-
missioners were included.
RESULTS
A total of 258 patients from 22 centres were recruited
into the study. Details of the participating centres are
presented in online supplementary table S1.
Patient baseline characteristics
The baseline characteristics of the patients included in
the study are presented in table 1. Of 258 patients
recruited, 65.1% were women and 62.4% had never
smoked (median pack-years in current/ex-smokers
(where available, n=52): 10.0 (range: 0.5–80.0)). The
mean age at diagnosis was 19.7 years and the mean dur-
ation of asthma was 25.1 years (table 1). The most
Table 1 Baseline patient characteristics
Variable
Total patient
cohort (n=258)
Age (years) 44.7 (14.2)
Female 168 (65.1%)
Smoker
Never 161 (62.4%)
Ex 83 (32.2%)
Current 6 (2.3%)
Unknown 8 (3.1%)
Weight (kg) 82.4 (20.1)
BMI (kg/m2)* 29.9 (6.8)
Ethnicity
White British 224 (86.8%)
Pakistani 19 (7.4%)
Other 15 (5.8%)
Duration of asthma (years)† 25.1 (15.1)
Age at asthma diagnosis (years)† 19.7 (17.9)
Allergies (most common)
House dust mite 176 (68.2%)
Animal fur 172 (66.7%)
Pollen 124 (48.1%)
Mould 88 (34.1%)
Plant material 86 (33.3%)
None documented 8 (3.1%)
Reported comorbidities (selected)
Perennial rhinitis 74 (28.7%)
Seasonal rhinitis 49 (19.0%)
Nasal polyps 37 (14.3%)
Sinusitis 35 (13.6%)
Previous anaphylaxis 22 (8.5%)
Bronchiectasis 9 (3.5%)
Diabetes 5 (1.9%)
None 74 (28.7%)
Data presented as mean (SD) or n (%).
*One patient did not have height recorded.
†Duration of asthma not recorded for 41 patients.
BMI, body mass index.
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common allergies were to house dust mite (68.2%),
animal fur (66.7%) and pollen (48.1%), with eight
patients (3.1%) having no documented allergies
(table 1) and 226 (87.6%) patients recorded as allergic
to one or more perennial aeroallergens. The most com-
monly reported comorbidities (see table 1) were peren-
nial (28.7%) and seasonal (19.0%) rhinitis, nasal polyps
(14.3%) and sinusitis (13.6%). The patient character-
istics of the CCS subgroup (n=76) were similar to those
of patients who were not on CCS (‘non-CCS’, n=136) at
baseline (see online supplementary table S2; insufﬁcient
data to classify OCS use, n=46). Of the 214 patients
treated with omalizumab at centres in England, 193
(90.2%) were compliant with NICE guidance and all 33
patients in Scotland (100%) were compliant with SMC
guidance (not applicable for n=11 patients from
Belfast). Of the original study population, 218 (84.5%)
patients completed the study (see online supplementary
ﬁgure S1).
Omalizumab dosing
Most patients (n=220; 84.9%) were dosed correctly from
available weight/baseline IgE measurements. Of the
remaining patients, 17 were eligible for dosing but
received the incorrect dose (based on recorded weight/
baseline IgE measurements), while 21 patients were
treated when their IgE levels or weight exceeded the
upper limits (all patients in this latter group received
600 mg every 2 weeks). The mean duration of omalizu-
mab treatment was 304 days (SD: 104) with a mean of
14.5 (SD: 7.1) omalizumab injections per patient during
the post-omalizumab study period.
Response to omalizumab
In the overall ITT patient group, there were 239 patients
with omalizumab response classiﬁed by treating physi-
cians at the 16-week assessment; 197 patients were classi-
ﬁed as responders and 42 as non-responders (response
rate: 82.4%; indeterminate response, n=6). Patients clas-
siﬁed as responders based on clinical assessment at
16 weeks were analysed as the responder subgroup in all
subsequent analyses (the characteristics of responders
and non-responders are presented in online supplemen-
tary table S2). The response rate was similar in the CCS
subgroup (61/73; 83.6%). At the end of the 12-month
post-omalizumab observation period, 179/258 patients
(69.4%) remained on omalizumab (see online supple-
mentary table S3 for reasons for discontinuing).
Impact of omalizumab on OCS use
The mean daily dose of OCS reduced signiﬁcantly during
the study period, as shown in ﬁgure 1A. In the ITT popu-
lation, mean daily dose decreased from 10.37 mg/day
per patient pre-omalizumab to 8.76 mg/day per patient
post-omalizumab (p<0.001). Similar signiﬁcant decreases
in mean daily OCS dose were observed in the responder
subgroup (9.83 mg/day per patient pre-omalizumab vs
7.77 mg/day per patient post-omalizumab, p<0.001) and
the CCS subgroup (15.40 mg/day pre-omalizumab vs
13.01 mg/day post-omalizumab, p<0.001). Patient weight
did not differ between the baseline and the 12-month
post-omalizumab visits (mean difference +0.71 (95% CI
−0.16 to 1.57) kg, n=202; p>0.1).
At the end of the 12-month post-omalizumab observa-
tion period, 15.8% (12/76) of the patients on CCS at
baseline had stopped taking OCS completely, with
42.1% (32/76) of the CCS patients either stopping or
reducing OCS by ≥20% at 12 months.
Impact of omalizumab on asthma exacerbations
The mean number of ‘hospital exacerbations’ (requiring
A&E attendance and/or admission) per patient
decreased signiﬁcantly during the study period, as
shown in ﬁgure 1B. In the ITT population, mean hos-
pital exacerbations per patient decreased from 1.66 pre-
omalizumab to 0.69 post-omalizumab (p<0.001). Similar
signiﬁcant decreases in hospital exacerbations were
observed in the responder subgroup (mean per patient
1.71 vs 0.66 pre-omalizumab and post-omalizumab,
respectively, p<0.001) and the CCS subgroup (1.20 vs
0.46 pre-omalizumab and post-omalizumab, respectively,
p<0.001).
Figure 1 Omalizumab treatment outcomes. (A) Steroid
sparing effect of omalizumab. (B) Impact of omalizumab on
hospital exacerbations. Data are presented as mean
difference (95% CIs) between the 12-month pre-omalizumab
and post-omalizumab periods. Paired t-test, p<0.001 for each
comparison. CCS, continuous corticosteroid; ITT, intention to
treat.
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Similarly, the mean number of ‘dose exacerbations’
(≥10 mg increase in OCS at any point for at least 3 days)
per patient decreased signiﬁcantly in the ITT population
(4.58 vs 2.53 pre-omalizumab and post-omalizumab,
respectively; mean difference −2.05 (95% CI −2.51 to
−1.59), p<0.001). Similar decreases were observed in the
responder subgroup (mean 4.62 vs 2.36 dose exacerba-
tions pre-omalizumab and post-omalizumab; mean dif-
ference −2.26 (95% CI −2.76 to −1.76), p<0.001) and
the CCS subgroup (mean 3.64 vs 2.40 dose exacerba-
tions pre-omalizumab and post-omalizumab; mean dif-
ference −1.25 (95% CI −2.04 to −0.46), p<0.01).
Impact of omalizumab on lung function
Mean FEV1% improved signiﬁcantly in the ITT group at
each post-omalizumab visit—baseline: 66.8%; 16 weeks:
71.4%; 8 months: 74.6%; 12 months: 71.3%; paired t-test
p<0.001 for each comparison (see ﬁgure 2A). Similar
increases in FEV1% were observed in the responder and
CCS subgroups, as shown in ﬁgure 2B, C, mirroring the
FEV1(L) data (see online supplementary ﬁgure S2).
Impact of omalizumab on PROs
A signiﬁcant improvement in PROs was observed when
assessed using asthma-speciﬁc ACT and AQLQ tools and
the generic EQ-5D in the overall ITT patient group, as
shown in table 2. Signiﬁcant improvements in each PRO
measure compared with baseline were observed at the
16-week post-omalizumab visit, which were maintained
throughout the 12-month post-omalizumab observation
period. Similar improvements were observed in the
responder and CCS subgroups (see online supplemen-
tary tables S4 and S5).
Socioeconomic impact
There was a signiﬁcant decrease in the mean number of
days off sick from work or education following treatment
(pre-omalizumab: 14.65 days; post-omalizumab 6.22 days;
mean difference −8.43 (−13.51 to −3.35) days, p<0.01;
n=63). There were 162 patients with complete data
regarding employment status during the study period; of
these, 21 of 93 (22.6%) patients who were unemployed
pre-omalizumab gained employment post-omalizumab.
By comparison, 6 of 69 (8.7%) patients employed pre-
omalizumab became unemployed.
Impact of omalizumab on resource utilisation
For the ITT population, the mean number of A&E visits,
inpatient hospitalisations, outpatient visits (excluding
visits for omalizumab administration) and number of
bed days per patient decreased signiﬁcantly in the
12-month post-omalizumab period compared with the
12-month pre-omalizumab period, as shown in table 3.
The number of ICU admissions also decreased signiﬁ-
cantly (22 admissions for 17 patients pre-omalizumab vs
12 admissions for 7 patients post-omalizumab; McNemar
test p<0.05). Similar results were observed in the
Figure 2 Impact of omalizumab on lung function. Data are
presented as mean difference (95% CIs) comparing assessments
at 16-week, 8-month and 12-month post-omalizumab with
baseline. (A) ITT patients, paired t-test, p<0.001 for each
comparison; (B) responder subgroup, paired t-test, p<0.001 for
each comparison; (C) CCS subgroup, paired t-test, p<0.001 for
16-week and 8-month comparisons and p<0.01 for 12-month
comparisons. CCS, continuous corticosteroid; FEV1, forced
expiratory volume in 1 s; ITT, intention to treat.
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responder and CCS subgroups (see online supplemen-
tary tables S6 and S7).
Safety of omalizumab
A total of 43 adverse events in 24 patients suspected to
be related to omalizumab treatment were reported; of
these, 19 were classiﬁed as serious (see online supple-
mentary table S8) and included one case of anaphylaxis
(with subsequent discontinuation of omalizumab treat-
ment) and one case of hypersensitivity reaction (subse-
quent action unknown). Two deaths were recorded (one
pneumonia and one respiratory arrest), neither of which
was suspected to be related to omalizumab treatment.
DISCUSSION
The results of the APEX II study of omalizumab used in
a ‘real-world’ clinical setting in the UK conﬁrm and add
to the available data on the beneﬁcial effects of omalizu-
mab on asthma outcomes.14–16 Omalizumab treatment
was associated with signiﬁcant reductions in mean daily
dose of OCS, asthma exacerbations, A&E visits, inpatient
hospitalisations, outpatient visits (excluding those for
omalizumab administration), hospital bed days and days
off sick from employment/education. It was also asso-
ciated with signiﬁcant improvements in lung function,
asthma-speciﬁc and generic PROs, and number of
patients in employment.
The proportion of patients responding to omalizumab
at the 16-week assessment was 82.4%, which is similar to
the response rate in APEX I and other observational
studies,14–16 19 including studies using similar mixed
methods approaches combining retrospective data col-
lection pre-omalizumab initiation with prospective data
collection following initiation.20–23 While most patients
in APEX II were dosed correctly, a small proportion of
patients were incorrectly dosed, including 21 patients
whose IgE levels or weight exceeded the upper limit.
While no information was available regarding the ration-
ale for dosing in these patients, it is of note that 19 were
classiﬁed as responders at 16 weeks and the magnitude
of effect on outcomes was similar to those of patients
appropriately treated according to UK guideline criteria
(data not shown). The proportion of patients who were
not treated according to dosing tables13 was lower in the
present study than has been previously reported.20
Table 2 PRO measures in the ITT patient group (paired samples)
16 weeks 8 months 12 months
ACT score n=222 n=177 n=187
Mean (SD) at baseline 9.76 (4.29) 9.77 (4.38) 9.84 (4.34)
Mean (SD) at visit 15.01 (5.71) 14.99 (5.78) 14.41 (5.69)
Mean difference (95% CI) 5.26 (4.58 to 5.93)* 5.22 (4.43 to 6.00)* 4.57 (3.75 to 5.38)*
AQLQ score n=192 n=149 n=161
Mean (SD) at baseline 3.27 (1.29) 3.14 (1.28) 3.20 (1.27)
Mean (SD) at visit 4.65 (1.55) 4.61 (1.54) 4.39 (1.48)
Mean difference (95% CI) 1.38 (1.18 to 1.58)* 1.47 (1.25 to 1.70)* 1.20 (0.97 to 1.42)*
EQ-5D index n=215 n=167 n=173
Mean (SD) at baseline 0.59 (0.25) 0.58 (0.26) 0.58 (0.25)
Mean (SD) at visit 0.71 (0.25) 0.68 (0.26) 0.69 (0.26)
Mean difference (95% CI) 0.12 (0.09 to 0.15)* 0.10 (0.06 to 0.13)* 0.11 (0.08 to 0.15)*
EQ-5D VAS n=196 n=162 n=166
Mean (SD) at baseline 54.2 (20.3) 53.5 (20.3) 54.3 (20.1)
Mean (SD) at visit 66.8 (21.2) 67.1 (21.9) 67.1 (20.9)
Mean difference (95% CI) 12.5 (9.5 to 15.5)* 13.6 (10.3 to 17.0)* 12.8 (9.4 to 16.2)*
*p<0.001.
ACT, Asthma Control Test; AQLQ, Asthma Quality of Life Questionnaire; EQ:5D VAS, EuroQol five-dimensions visual analogue scale; ITT,
intention to treat; PRO, patient-reported outcome.
Table 3 Resource utilisation in the ITT patient group
Pre-omalizumab (n=218) Post-omalizumab (n=218) Mean difference (95% CI)
A&E visits/patient 1.12 (1.71) 0.37 (0.91) −0.75 (−0.99 to −0.52), p<0.001
Inpatient admissions/patient 1.24 (1.64) 0.56 (1.33) −0.68 (−0.85 to −0.51), p<0.001
Outpatient visits/patient* 4.60 (2.48) 1.60 (2.07) −3.00 (−3.43 to −2.58), p<0.001
Bed days/patient 6.61 (9.73) 3.39 (8.49) −3.22 (−4.31 to −2.12), p<0.001
Day case visits/patient 0.03 (0.18) 0.03 (0.19) 0.00 (−0.04 to 0.03), p>0.01
Data are presented as mean (SD).
*Excluding visits for omalizumab administration.
ITT: intention to treat.
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The primary outcome measure (mean daily dose of
OCS) decreased signiﬁcantly in the 12-month post-
omalizumab period, and 42.1% of patients on CCS at
baseline had reduced or stopped OCS, consistent with
the results of previous studies.15 19 21 23 The magnitude
of reduction in mean OCS daily dose was smaller than
that observed in APEX I, although the mean daily dose
pre-omalizumab was half of that observed in APEX I,
which may reﬂect changes in NICE guidance regarding
patient eligibility for omalizumab treatment in the inter-
vening period. The differences in study design may also
have contributed to the differences in the magnitude of
reduction in OCS, with prospective data collection post-
omalizumab initiation in APEX II resulting in a more
accurate assessment of OCS use compared with APEX
I. The observed reduction in OCS is indicative of
improved asthma control, and more importantly, the
number of patients ceasing CCS use is of considerable
clinical importance given the morbidity associated with
long-term OCS.8–12 We did not observe a decrease in
weight at the 12-month visit compared with baseline
despite the known association between OCS use and
weight gain,10 suggesting that OCS-associated weight
gain is not readily lost upon dose reduction and reﬂect-
ing the multifactorial nature of successful weight loss.
We observed a signiﬁcant reduction in asthma exacer-
bations (as assessed by hospitalisation (including A&E
attendance) or OCS dose increase ≥10 mg for at least
3 days) in the ITT, responder and CCS subgroups.
Similar reductions in exacerbations have been reported
previously, although the criteria used to deﬁne exacerba-
tions differed16 20 23 or were not speciﬁed.21 22 We also
observed a modest but signiﬁcant improvement in lung
function in the post-omalizumab period in all groups
evaluated, which was observed by 16 weeks of treatment.
While improvements in lung function compared with
baseline were maintained throughout the 12-month
follow-up period, similar to other studies,16 20 the great-
est improvements were observed at 8 months in the ITT,
responder and CCS subgroups, which may suggest
attenuation of response in some patients by 12 months.
QoL improved signiﬁcantly in the ITT, responder and
CCS patient groups when assessed using each of the
three PRO instruments, demonstrating an improvement
in asthma control (ACT score), asthma-related QoL
(AQLQ) and general QoL (EQ-5D), consistent with pre-
vious studies, including one or more of these PRO mea-
sures.16 20 24 25 It has been demonstrated that a change
in AQLQ score of 0.5 in adults with asthma represents
the minimal important difference in QoL, with changes
of 1.0 and 1.5 representing moderate and large changes
in QoL, respectively.26 The observed absolute reduction
in AQLQ of 1.4 at 16 weeks in the ITT population in the
present study, therefore, suggests a moderate to large
effect of omalizumab on QoL. It should, however, be
noted that the mean ACT scores post-omalizumab
remained <19, indicating that asthma control was still
classiﬁed as poor despite the observed reduction in OCS
use and improvements in exacerbations and lung func-
tion. We also identiﬁed a signiﬁcant reduction in time
off sick from employment/education, consistent with
the results of a previous small study.22 Importantly, we
identiﬁed 21 patients who returned to work in the post-
omalizumab period, suggesting a wider beneﬁcial socio-
economic impact associated with treatment of patients
with severe allergic asthma with omalizumab. While
these data are subject to recall bias, the suggested
improvement in work and education attendance and
employment status represents an important health eco-
nomic outcome and is also highly important in the
context of patient QoL.
Omalizumab treatment was also associated with a sig-
niﬁcant reduction in hospital A&E visits and inpatient
hospitalisations, consistent with previous studies16 20–23
and with a signiﬁcant reduction in ICU admissions. This
supports the beneﬁcial effects of omalizumab in redu-
cing resource utilisation associated with emergency and
inpatient admissions. We also identiﬁed a signiﬁcant
reduction in outpatient attendances excluding those for
omalizumab administration; however, we cannot exclude
that consultant-led outpatient attendances were reduced
as a result of the increased frequency with which
patients were seen by another healthcare professional
for omalizumab administration. The impact of omalizu-
mab on total hospital resource utilisation should take
into account the reductions in A&E and inpatient admis-
sions and consultant-led outpatient visits in addition to
the resources associated with the administration of oma-
lizumab for health economic evaluations.
Taken together, the available data support a beneﬁcial
effect of omalizumab on asthma outcomes. However, it
cannot be excluded that the reduction in OCS use and
other beneﬁcial effects observed in this and previous
studies may, at least in part, be attributable to the
increased frequency with which patients are seen by
healthcare professionals for omalizumab injections,
which may lead to an improvement in compliance with
OCS and other medications.
In addition, the differing methodology for collection
of data in the pre-omalizumab/post-omalizumab initi-
ation periods in APEX II introduced a potential infor-
mation bias. The pre-omalizumab period relied on the
quality and completeness of medical records, which was
reﬂected in the volume of missing data for some vari-
ables, leading to differences in the number of patients
included in each analysis. In particular, details of OCS
prescriptions provided in primary care were limited in
the pre-omalizumab period which may have led to
under (or over)estimation of the number of patients
classiﬁed as on CCS and calculation of the mean daily
dose in the pre-omalizumab period. In addition, any
hospital or A&E visits other than at the study centre
would not have been identiﬁed. In contrast, the pro-
spective data collection in the post-omalizumab period
allowed for more complete data collection related to
OCS use and asthma-related outcomes. However, there
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were a number of patients with missing data at different
time-points and overall 40 patients lost to follow-up/
withdrawn/excluded/died which may have led to an
overestimation of the impact of omalizumab in the ITT
analyses. Given the cyclical nature of asthma symptoms,
we are also unable to exclude an inﬂuence of regression
to the mean on patient outcomes.
Data related to days off sick from work/education
were subject to recall bias in pre-omalizumab and post-
omalizumab periods; however, the recall periods
between post-omalizumab visits were shorter and more
likely to be accurate compared with data recalled for the
12-month pre-omalizumab period. It seems unlikely that
reported employment status pre-omalizumab and post-
omalizumab was subject to recall bias in the same way,
and therefore, the increase in the number of patients in
employment in the post-omalizumab period tends to
support the observed beneﬁcial effect of omalizumab in
reducing days off sick.
A key strength of APEX II lies in the fact that data
were collected in a non-interventional clinical setting,
and therefore, the results reﬂect the outcomes of
patients when treated according to normal UK clinical
practice in an unselected patient population. These data
can, therefore, be considered to be generalisable to the
wider UK population of adult patients (aged>16 years)
with allergic asthma treated with omalizumab.
In conclusion, data from the present study indicate
that omalizumab used in a ‘real-world’ clinical setting in
the UK is associated with decreased OCS usage,
decreased asthma exacerbations, improved lung func-
tion, improved work/education attendance and employ-
ment, and decreased A&E and inpatient resource
utilisation. These data are of relevance to clinicians,
payers and healthcare commissioners, adding to and
extending the growing body of evidence, derived from dif-
ferent countries and differing study designs, supporting
the beneﬁcial effects of omalizumab on asthma-related
outcomes, QoL and resource utilisation in unselected
patients treated in normal clinical practice. The growing
evidence of a wider socioeconomic impact of omalizumab
treatment merits further exploration; the long-term
funding of this and other moderate to high cost monoclo-
nal therapies should consider the impact of all societal
costs in costing models. A proportion of patients coming
off beneﬁts and contributing to the economy positively
may offset some of the drug and delivery of care costs if
such data are reproduced.
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